VA/DoD 2026 Guideline Designates Varenicline and Dual NRT as First-Line Tobacco Cessation Options
The 2026 VA/DoD guideline elevates varenicline and combination NRT as preferred cessation treatments after systematic review of recent trials. It stresses safety in mental health populations and immediate retreatment after relapse, carrying implications for veteran morbidity reduction. Evidence rests on synthesized RCTs with calls for pragmatic implementation data.
Implementation across the VA system could affect the 18 percent of veterans who currently smoke, a population with elevated cardiovascular and cancer burden. Real-world adherence and access barriers in active-duty settings remain untested. Future studies must report long-term cardiovascular outcomes and cost-effectiveness in integrated health systems.
VA: By end of 2027, documented use of varenicline or dual NRT will exceed 60 percent of pharmacotherapy prescriptions for tobacco use within the VA system.
Sources (3)
- [1]Primary Source(https://www.acpjournals.org/doi/10.7326/ANNALS-26-01499)
- [2]Supporting Source(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009329.pub4/full)
- [3]Supporting Source(https://jamanetwork.com/journals/jama/fullarticle/2801234)